

Generics BRIC (Brazil, Russia, India, China) Industry Guide 2019-2028

Industry Report | 2024-12-20 | 240 pages | MarketLine

AVAILABLE LICENSES:

- Single user licence (PDF) \$995.00
- Site License (PDF) \$1492.00
- Enterprisewide license (PDF) \$1990.00

Report description:

Generics BRIC (Brazil, Russia, India, China) Industry Guide 2019-2028

Summary

The BRIC Generics industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume, and forecast to 2028). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Key Highlights

- Brazil, Russian Federation, India and China (BRIC) are the emerging and fast growing countries within the generics industry and had a total market value of \$1,68,484.5 million in 2023. Russia was the fastest growing country with a CAGR of 16.2% over the 2019-23 period.
- Within the generics industry, China is the leading country among the BRIC nations with market revenues of \$1,21,016.7 million in 2023. This was followed by India, Russia and Brazil with a value of \$22,824.0, \$15,429.5, and \$9,214.4 million, respectively.
- China is expected to lead the generics industry in the BRIC nations with a value of \$1,77,196.9 million in 2028, followed by India, Russia, Brazil with expected values of \$31,455.5, \$19,230.3 and \$14,400.1 million, respectively.

Scope

- Save time carrying out entry-level research by identifying the size, growth, and leading players in the BRIC generics market
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the BRIC generics market
- Leading company profiles reveal details of key generics market players' BRIC operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the BRIC generics market with five year forecasts by both value and volume

- Compares data from Brazil, Russia, India, and China, alongside individual chapters on each country

Reasons to Buy

- What was the size of the BRIC generics market by value in 2023?
- What will be the size of the BRIC generics market in 2028?
- What factors are affecting the strength of competition in the BRIC generics market?
- How has the market performed over the last five years?
- How large is the BRIC generics market in relation to its regional counterparts?

Table of Contents:

Table of Contents

- 1 Introduction
- 1.1. What is this report about?
- 1.2. Who is the target reader?
- 1.3. How to use this report
- 1.4. Definitions
- 2 BRIC Generics
- 2.1. Industry Outlook
- 3 Generics in Brazil
- 3.1. Market Overview
- 3.2. Market Data
- 3.3. Market Segmentation
- 3.4. Market outlook
- 3.5. Five forces analysis
- 4 Macroeconomic Indicators
- 4.1. Country data
- 5 Generics in China
- 5.1. Market Overview
- 5.2. Market Data
- 5.3. Market Segmentation
- 5.4. Market outlook
- 5.5. Five forces analysis
- 6 Macroeconomic Indicators
- 6.1. Country data
- 7 Generics in India
- 7.1. Market Overview
- 7.2. Market Data
- 7.3. Market Segmentation
- 7.4. Market outlook
- 7.5. Five forces analysis
- 8 Macroeconomic Indicators
- 8.1. Country data
- 9 Generics in Russia
- 9.1. Market Overview
- 9.2. Market Data
- 9.3. Market Segmentation

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com www.scotts-international.com

- 9.4. Market outlook
- 9.5. Five forces analysis
- 10 Macroeconomic Indicators
- 10.1. Country data
- 11 Company Profiles
- 11.1. Teva Pharmaceutical Industries Ltd
- 11.2. Viatris Inc
- 11.3. Sun Pharmaceutical Industries Ltd
- 11.4. Novartis AG
- 11.5. Sandoz Group AG
- 11.6. Hikma Pharmaceuticals Plc
- 11.7. Sanofi
- 11.8. Les Laboratoires Servier SAS
- 11.9. Stada Arzneimittel AG
- 11.10. Bayer AG
- 11.11. Lupin Ltd
- 11.12. Aspen Pharmacare Holdings Ltd
- 11.13. EMS SA
- 11.14. Eurofarma Laboratorios SA
- 11.15. Ache Laboratorios Farmaceuticos SA
- 11.16. Apotex Inc
- 11.17. Teva Canada Ltd
- 11.18. Sandoz Canada Inc
- 11.19. CSPC Pharmaceutical Group Ltd
- 11.20. Sino Biopharmaceutical Ltd
- 11.21. Hansoh Pharmaceutical Group Co Ltd
- 11.22. Dr. Reddy's Laboratories Ltd
- 11.23. Cipla Ltd
- 11.24. Aurobindo Pharma Ltd
- 11.25. PT Kalbe Farma Tbk
- 11.26. PT Indofarma Tbk
- 11.27. PT Sanbe Farma
- 11.28. PT Soho Global Health Tbk
- 11.29. Friulchem SpA
- 11.30. DOC Generici SRL
- 11.31. Recordati SpA
- 11.32. Daiichi Sankyo Co Ltd
- 11.33. Towa Pharmaceutical Co Ltd
- 11.34. Sawai Group Holdings Co Ltd
- 11.35. Toho Holdings Co Ltd
- 11.36. Laboratorios Silanes SA de CV
- 11.37. Pfizer Inc
- 11.38. Biocad
- 11.39. R-Pharm
- 11.40. Pharmstandard
- 11.41. AstraZeneca Plc
- 11.42. Bluefish Pharmaceuticals AB

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com www.scotts-international.com

- 11.43. Navamedic ASA
- 11.44. Novartis International AG
- 11.45. Beacons Pharmaceuticals Pte Ltd
- 11.46. Abbott Laboratories SA
- 11.47. Adcock Ingram Holdings Ltd
- 11.48. Dongkook Pharmaceutical Co Ltd
- 11.49. JW Holdings Corp
- 11.50. Hanmi Pharmaceuticals Co Ltd
- 11.51. Dong Wha Pharma Co Ltd
- 11.52. Esteve Pharmaceuticals SA
- 11.53. Abdi Ibrahim Ilac Sanayi ve Ticaret AS
- 11.54. Deva Holding AS
- 11.55. Sandoz Inc
- 12 Appendix
- 12.1. Methodology
- 12.2. About MarketLine



☐ - Print this form

To place an Order with Scotts International:

 $\hfill \Box$ - Complete the relevant blank fields and sign

Generics BRIC (Brazil, Russia, India, China) Industry Guide 2019-2028

Industry Report | 2024-12-20 | 240 pages | MarketLine

Select license	License				Price
	Single user licence (PDF)				\$995.00
	Site License (PDF)				\$1492.00
	Enterprisewide license (PDF)				\$1990.00
				VAT	
				Total	
	d at 23% for Polish based companies,	individuals and EU based co	mpanies who are u	unable to provide a	valid EU Va
Email*	d at 23% for Polish based companies,	_	mpanies who are u	unable to provide a	valid EU Va
Email* First Name*	d at 23% for Polish based companies,	Phone*	mpanies who are u	unable to provide a	valid EU Va
Email* First Name* ob title*	d at 23% for Polish based companies,	Phone*		unable to provide a	valid EU Va
Email* First Name* ob title* Company Name*	d at 23% for Polish based companies,	Phone* Last Name*		unable to provide a	valid EU Va
Email* First Name* lob title* Company Name* Address*	d at 23% for Polish based companies,	Phone* Last Name* EU Vat / Tax ID / I		unable to provide a	valid EU Va
]** VAT will be added Email* First Name* Job title* Company Name* Address* Zip Code*	d at 23% for Polish based companies,	Phone* Last Name* EU Vat / Tax ID / I City*		unable to provide a	valid EU Va

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com www.scotts-international.com